Immunotherapy for gynaecological malignancies.

Journal Article (Journal Article;Review)

Gynaecological malignancies, excluding breast cancer, cause approximately 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of preventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

Full Text

Duke Authors

Cited Authors

  • Coukos, G; Conejo-Garcia, JR; Roden, RBS; Wu, T-C

Published Date

  • September 2005

Published In

Volume / Issue

  • 5 / 9

Start / End Page

  • 1193 - 1210

PubMed ID

  • 16120050

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

Digital Object Identifier (DOI)

  • 10.1517/14712598.5.9.1193


  • eng

Conference Location

  • England